key: cord-0919873-kbt5gdyy
authors: Seydoux, Emilie; Homad, Leah J.; MacCamy, Anna J.; Parks, K. Rachael; Hurlburt, Nicholas K.; Jennewein, Madeleine F.; Akins, Nicholas R.; Stuart, Andrew B.; Wan, Yu-Hsin; Feng, Junli; Nelson, Rachael E.; Singh, Suruchi; Cohen, Kristen W.; McElrath, M. Juliana; Englund, Janet A.; Chu, Helen Y.; Pancera, Marie; McGuire, Andrew T.; Stamatatos, Leonidas
title: Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
date: 2020-05-12
journal: bioRxiv
DOI: 10.1101/2020.05.12.091298
sha: ddfa67125769a18a947f58e29c6bf929abc6dca8
doc_id: 919873
cord_uid: kbt5gdyy

B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one days post-infection. Forty-four S2P-specific monoclonal antibodies were generated, three of which bound to the receptor binding domain (RBD). The antibodies were minimally mutated from germline and were derived from different B cell lineages. Only two antibodies displayed neutralizing activity against SARS-CoV-2 pseudo-virus. The most potent antibody bound the RBD in a manner that prevented binding to the ACE2 receptor, while the other bound outside the RBD. Our study indicates that the majority of antibodies against the viral envelope spike that were generated during the first weeks of COVID-19 infection are non-neutralizing and target epitopes outside the RBD. Antibodies that disrupt the SARS-CoV-2 spike-ACE2 interaction can potently neutralize the virus without undergoing extensive maturation. Such antibodies have potential preventive/therapeutic potential and can serve as templates for vaccine-design. IN BRIEF SARS-CoV-2 infection leads to expansion of diverse B cells clones against the viral spike glycoprotein (S). The antibodies bind S with high affinity despite being minimally mutated. Thus, the development of neutralizing antibody responses by vaccination will require the activation of certain naïve B cells without requiring extensive somatic mutation. Highlights Analysis of early B cell response to SARS-CoV-2 spike protein Most antibodies target non-neutralizing epitopes Potent neutralizing mAb blocks the interaction of the S protein with ACE2 Neutralizing antibodies are minimally mutated

Serum and PBMC were collected twenty-one days after the onset of clinical disease. The 107 serum contained high titers of antibodies to the SARS-CoV-2 S2P (Fig. 1A) . The 108 specificity of this response was confirmed by the absence of S2P reactivity by serum 109 antibodies isolated from donors collected prior to the SARS-CoV-2 pandemic, or donors 110 with confirmed infection by endemic coronaviruses. We also measured the serum 111 antibody response to RBD, and again observed specific high titers of binding antibodies 112 (Fig. 1B) . Isotype-specific ELISA revealed that the IgG titers were higher than the IgA and 113 the IgM titers to both S2P and RBD, suggesting a significant portion of the antibody 114 responses to SARS-CoV-2 S are IgG ( Fig. 1C and D) . The serum from the SARS-CoV-2 115 infected donor displayed potent neutralizing activity (Reciprocal ID50~3000)against a 116 pseudovirus expressing the S protein from SARS-CoV-2 isolate Wuhan-Hu-1 (Fig 1E) . 117 We concluded that this donor had developed strong binding and neutralizing antibody 118 responses within three weeks of disease onset. 120 Fluorescently labeled S2P and RBD probes were used as baits to identify B cells specific 121 to the SARS-CoV-2 S protein that were circulating at this timepoint. S2P was labeled with 122 either phycoerythrin (PE) or brilliant violet 711 (BV711) and used to stain B cells 123 concurrently. This double labeling strategy helps to discriminate between bona fide S2P- Among all successfully sequenced VH and VL transcripts, we obtained paired sequences 147 from forty-four. These were produced as recombinant monoclonal antibodies (mAbs) of 148 the IgG1 isotype and tested for binding to recombinant S-derived proteins (Fig. 3) . 149 All the mAbs bound to the stabilized SARS-CoV-2 ectodomain, S2P ( Fig. 3A and E).

Consistent with the B cell staining that revealed very few RBD-specific B cells (Fig. 2B) , 151 only three mAbs, CV5, CV30 and CV43, also bound the SARS-CoV-2 RBD ( Fig. 3B and 152 E). The majority of S2P-specific mAbs also bound to full-length membrane-bound 153 wildtype SARS-CoV-2 S on the surface of 293 cells ( Fig. 3C and Fig. S2 ). The observation 154 that some S2P-specific mAbs failed to bind to cell surface S indicates that there may be 155 conformational differences between the stabilized soluble ectodomain and cell surface S.

The fact that a subset of the mAbs bound to a stabilized ectodomain variant of the closely 157 related SARS-CoV S protein ( Fig. 3D and E), demonstrates that there are conserved 158 epitopes among the two viruses. Consistent with the lower degree of conservation of the 159 S1 subunit between SARS-CoV and SARS-CoV-2, the anti-RBD mAbs CV30 and CV43 160 did not cross react with SARS-CoV S2P, while CV5 showed weak binding.

Neutralizing activity 162 The S2P-binding mAbs were evaluated for their ability to neutralize SARS CoV-2 163 pseudovirus infection of 293T cells stably expressing ACE2. All but two of the mAbs were 164 non-neutralizing ( Fig. 4A and Table S1 ). Although it did not achieve 100% neutralization 165 at the highest concentration, CV1 which binds an epitope outside the RBD was weakly 166 neutralizing (IC50=15µg/ml, Fig. 4A and Table S1 ). CV1 neutralized less potently than an 167 ACE2-Fc fusion protein which acts as a soluble competitor for the interaction between S 168 9 and the cell surface-expressed ACE2 (IC50=2.2 µg/ml). In contrast, CV30 achieved 100% 169 neutralization and was ~480 times more potent than CV1 (IC50=0.03µg/ml, Fig. 4A and 170   Table S1 ). CV1, CV30 and the ACE2-Fc fusion did not neutralize a murine leukemia virus 171 pseudovirus demonstrating their specificity for the SARS-CoV-2 S protein (Fig. 4B ). CV30 (Table S1 ).

Based on the observations that CV30 is potently neutralizing and it binds RBD with high We thank Todd Haight for specimen processing. Table S1 for details). (B) The same mAbs were tested for neutralization of an MLV Table S2 . mAbs that showed >50% neutralization at 50µg/ml, or plasma were further analyzed to 514 determine neutralizing potency, by preparing serial dilutions and conducting the 515 neutralization assay as described above. The antibody concentration or plasma dilution 516 that neutralized 50% of infectivity (IC50 or ID50, respectively) was interpolated from the 517 neutralization curves determined using the log(inhibitor) vs. response --Variable slope 518 (four parameters) fit using automatic outlier detection in Graphpad Prism Software. As a 519 control for specificity SARS CoV2-mAbs were tested for neutralizing activity against HIV-520 1 derived virions pseudotyped with murine leukemia virus envelope (MLV). 

Efficient generation of monoclonal antibodies from single human B cells by 629 single cell RT-PCR and expression vector cloning

An efficient method to make 633 human monoclonal antibodies from memory B cells: potent neutralization of SARS 634 coronavirus

High-Quality Library Preparation for NGS-Based 637

Immunoglobulin Germline Gene Inference and Repertoire Expression Analysis. 638 Frontiers in immunology 10

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Unexpected Receptor Functional 644

Mimicry Elucidates Activation of Coronavirus Fusion

Receptor Recognition by 646 the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural 647 Studies of SARS Coronavirus

A human 650 monoclonal antibody blocking SARS-CoV-2 infection

WHO announces COVID-19 outbreak a pandemic

Cryo-EM structure of the 2019-nCoV spike in the 654 prefusion conformation

Exceptionally potent neutralization of Middle East respiratory 657 syndrome coronavirus by human monoclonal antibodies

Junctional and allele-specific residues are critical for 661

MERS-CoV neutralization by an exceptionally potent germline-like antibody

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins 668 reveal the dynamic receptor binding domains